SynAct Pharma
SynAct Pharma to participate at BIO International Convention in Boston June 16-19
SynAct Pharma AB (publ) (“SynAct”) (Nasdaq Stockholm: SYNACT), a clinical-stage biotechnology company focused on resolving inflammation through selective activation of the melanocortin system, today announced that the company will participate in the BIO International Convention in Boston, USA, June 16-19, 2025.
The BIO International Convention is the largest and most comprehensive partnering event in biotech, bringing together over 20,000 industry leaders from across the globe. The event offers a premier platform for networking, knowledge exchange, and business development within the biotech sector.
“We look forward to participating at BIO 2025 to engage with potential partners and investors, and to showcase our development programs with Resomelagon (AP1189),” said Jeppe Øvlesen, CEO of SynAct.
During the event, Synact’s Chairman Anders Kronborg, Chief Business Officer James Knight, Chief Scientific Officer Thomas Jonassen and CEO Jeppe Øvlesen will be available for one-on-one meetings through the BIO partnering platform.
Read more about the BIO International Convention: https://www.bio.org/events/bio-international-convention
| Datum | 2025-04-16, kl 08:00 |
| Källa | MFN |
SAVR är investeringsplattformen som utmanar branschen och gör det både enklare och roligare att investera. Betala aldrig för mycket! Alla aktier och ETF:er från 1 kr, och få upp till 50 % rabatt på alla fonder. Automatiskt courtage och samma enkla prismodell på alla marknader.